文献速递其他结缔组织病

基于人类遗传学证据优化系统性硬化症药物开发优先靶点

Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该研究通过GWAS Catalog检索SSc遗传变异,将映射基因与OpenTargets平台交叉引用以识别可成药靶点,并通过文献和临床试验注册库验证。共识别89种独特药物,均未纳入现有SSc指南,其中抗OX40L单抗Amlitelimab正在CONQUEST平台试验中评估用于SSc相关间质性肺病。

要点

  • 整合遗传学与生物信息学可识别SSc药物重定位机会。
  • 识别89种药物,无一被现有SSc指南/推荐收录。
  • 神经递质靶向药物与SSc相关雷诺现象和胃肠道受累相关。

核心结论

  • 整合多生物信息学平台证据的系统性方法可识别SSc药物重定位和可成药靶点机会。

研究设计与样本

  • 通过GWAS Catalog检索SSc遗传变异,将关联映射基因与OpenTargets平台交叉引用药物相互作用,并通过MEDLINE和ClinicalTrials.gov结构化文献检索验证每个药物与SSc的关联。

主要发现

  • 共识别89种独特药物,均未纳入现有SSc指南/推荐。
  • Amlitelimab(抗OX40L单抗)正在CONQUEST多中心随机对照平台试验中评估用于SSc间质性肺病。
  • 药物分组主要包括女性性激素及功能、神经递质靶向治疗和炎症-纤维化通路。
  • JAK/STAT通路是SSc中有吸引力的治疗靶点,针对已知病理生物学。
  • 意外发现多种神经递质靶向药物,尤其与SSc相关雷诺现象和胃肠道受累相关。

临床怎么用

  • 许多候选药物广泛可及且常价格低廉,未来可开展SSc药物重定位研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: SSc is a rare rheumatological disease associated with significant morbidity and mortality. Despite significant recent international clinical trial activity, the yield of approved compounds has been disappointingly low. Our aim was to identify and prioritize potential 'druggable' targets with insights from human genetics, by integrating the available evidence with publicly available bioinformatics sources relevant for SSc drug development. METHODS: Genetic variants for SSc were identified through a search of the GWAS Catalog, and the associated-mapped genes were cross-referenced with the OpenTargets platform for drug interactions. Confirmation/validation was demonstrated through structured literature searches and review of the evidence on MEDLINE and ClinialTrials.gov for each individual drug and its association with SSc. RESULTS: We identified 89 unique drugs, none of which is included in existing SSc guidelines/recommendations. Amlitelimab (anti-OX40L mAb) is currently being explored in CONQUEST (Platform Clinical Study for Conquering Scleroderma), a multicentre randomized controlled platform trial for SSc interstitial lung disease. Key groupings of drug therapies were (i) female sex hormones and function, (ii) neurotransmitter-targeting therapies, and (iii) inflammatory-fibrotic pathways. The Janus kinase (JAK)/STAT pathway is an attractive therapeutic target in SSc, targeting known pathobiology. CONCLUSION: Our systematic approach, combining evidence from different bioinformatics platforms, has identified drug opportunities for repurposing/druggable targets for SSc. A novel and unexpected finding was the identification of multiple neurotransmitter-targeting drug therapies, particularly relevant to SSc-related RP and gastrointestinal involvement. Future studies of these candidates for SSc drug repurposing, many of which are widely available and often inexpensive, are indicated.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hughes M, McMahan ZH, Assassai S, et al. Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies. Rheumatology (Oxford). 2026. PMID: 41689177. doi:10.1093/rheumatology/keag084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。